- Home
- SITC vs AMRN Comparison
SITC vs AMRN Comparison
Compare SITC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.30
HOLD
Current Price
$16.56
Company Overview
Basic Information| Metric | SITC | AMRN |
|---|---|---|
| Founded | 1965 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 339.8M |
| IPO Year | 1993 | 1993 |
Fundamental Metrics
Financial Performance| Metric | SITC | AMRN |
|---|---|---|
| Price | $7.30 | $16.56 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $12.63 | $12.00 |
| AVG Volume (30 Days) | ★ 1.1M | 76.2K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 78.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | $139,962,000.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $7.08 |
| 52 Week High | $15.93 | $20.90 |
Technical Indicators
Market Signals| Indicator | SITC | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 50.81 |
| Support Level | $7.17 | $15.36 |
| Resistance Level | $7.41 | $16.25 |
| Average True Range (ATR) | 0.16 | 0.67 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 73.29 | 60.32 |
Price Performance
Historical Comparison SITC
AMRN
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.